GlassScriptPhysician profile
Debra Lynn Howard
NPI 1164942355
$2,710.61
in general payments reported to CMS, 2019-2025
24 companies · $181 in 2025
The $181 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $873 · 2022: $864 · 2023: $496 · 2024: $297 · 2025: $181.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $974.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $973.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $884.02 | 2021-2023 | |
| Aspira Women'S Health INC | $282.15 | 2021-2023 | Ova1 |
| Myovant Sciences INC. | $228.48 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $225.76 | 2021-2025 | |
| Sumitomo Pharma America, INC. | $203.62 | 2023-2024 | Myfembree |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2021 | |
| Daiichi Sankyo INC. | $113.51 | 2021-2024 | Injectafer |
| Astellas Pharma US INC | $101.07 | 2022-2025 | Veozah |
| Sage Therapeutics, LLC | $81.65 | 2024-2025 | Zurzuvae |
| Novo Nordisk INC | $69.58 | 2023-2024 | Wegovy, Saxenda |
| Hologic Sales and Service, LLC | $63.53 | 2021-2025 | Thinprep 2000 Processor, Aptima |
| Pfizer INC. | $62.04 | 2024-2025 | |
| Agile Therapeutics, INC. | $37.68 | 2021-2022 | |
| Lilly USA, LLC | $36.23 | 2024 | Zepbound |
| Organon LLC | $30.04 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $27.05 | 2023 | Slynd |
| Therapeuticsmd, INC. | $26.40 | 2021 | |
| Becton, Dickinson and Company | $23.24 | 2022 | |
| Millicent US INC | $19.47 | 2025 | Femlyv |
| Lupin INC. | $17.17 | 2021 | |
| Avion Pharmaceuticals | $16.17 | 2021 | |
| Merck Sharp & Dohme LLC | $13.60 | 2021 | |
| Shield Therapeutics INC | $13.54 | 2023 | Accrufer |
| Neuronetics, INC. | $9.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Debra Howard listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.